title: Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
authors.affiliation: Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden.
authors.forename: Henrik
authors.initials: H
authors.lastname: Kindmark
authors.forename: Eva Tiensuu
authors.initials: ET
authors.lastname: Janson
authors.forename: Bengt
authors.initials: B
authors.lastname: Gustavsson
authors.forename: Camilla
authors.initials: C
authors.lastname: Eriksson
authors.forename: Gunnel
authors.initials: G
authors.lastname: Larsson
authors.forename: Dan
authors.initials: D
authors.lastname: Granberg
authors.forename: Gordana
authors.initials: G
authors.lastname: Kozlowacki
authors.forename: Britt
authors.initials: B
authors.lastname: Skogseid
authors.forename: Staffan
authors.initials: S
authors.lastname: Welin
authors.forename: Kjell
authors.initials: K
authors.lastname: Oberg
authors.forename: Barbro
authors.initials: B
authors.lastname: Eriksson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000378:metabolism; D004701:Endocrine Gland Neoplasms / Q000188:drug therapy / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor